Purpose A long natural history and a predominant osseous pattern of metastatic spread are
impediments to the adoption of precision medicine in patients with prostate cancer. To …

Importance Germline gene panel testing is recommended for men with advanced prostate
cancer (PCa) or a family history of cancer. While evidence is limited for some genes …

Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …

BACKGROUND: Most personalized cancer care strategies involving DNA sequencing are
highly reliant on acquiring sufficient fresh or frozen tissue. It has been challenging to …

Background Global disparities in prostate cancer (PCa) incidence highlight the urgent need
to identify genomic abnormalities in prostate tumors in different ethnic populations including …

PURPOSE Comprehensive genomic profiling (CGP) is increasingly used for routine clinical
management of prostate cancer. To inform targeted treatment strategies, 3,476 clinically …

Background There are multiple existing and emerging therapeutic avenues for metastatic
prostate cancer, with a common denominator, which is the need for predictive biomarkers …

Prostate cancer is the most commonly diagnosed non-cutaneous neoplasm among
American males and is the second leading cause of cancer-related death. Prostate specific …

Advanced prostate cancer can progress to systemic metastatic tumors, which are generally
androgen insensitive and ultimately lethal. Here, we report a comprehensive genomic …

DNA sequencing has identified recurrent mutations that drive the aggressiveness of prostate
cancers. Surprisingly, the influence of genomic, epigenomic, and transcriptomic …